Objective To explore the international research status and hotspots of safe medication in children with atopic dermatitis (AD), and to provide references for domestic treatment protocols and research development in this field.

Methods Based on the Web of Science Core Collection, English-language literature was retrieved from inception to December 8, 2025. CiteSpace software was used to analyze the country/region, institution, discipline category, keyword co-occurrence, clustering and emergence analysis.

Results A total of 1,065 articles were included, annual publications showed an upward trend. The research institutions were mainly universities and hospitals. This field of research encompasses a range of disciplines, including dermatology, immunology and allergology. Research hotspots focused on drug safety (e.g., pimecrolimus, tacrolimus, dupilumab), comorbidity management (e.g., food allergy, asthma), and treatment guidelines, with increasing attention to the long-term safety of systemic targeted therapies and comprehensive management strategies.

Conclusions Research on safe medication for pediatric AD is becoming increasingly active, showing an evolving trend from safety evaluation of traditional topical medications to long-term safety of systemic targeted therapies and comprehensive management strategies. China's standing in this field is rapidly rising, and in the future, real-world research and the localized guidelines will be further developed to improve the safety of pediatric medicines.

1. MiltnerLA, VonkJM, Van Der VeldeJL, et al. Eczema in early childhood increases the risk of allergic multimorbidity[J]. Clin Transl Allergy, 2024, 14(9): e12384. DOI: 10.1002/clt2.12384.

2. StefanovicN, IrvineAD. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives[J]. Ann Allergy Asthma Immunol, 2024, 132(2): 187-195. DOI: 10.1016/j.anai.2023.09.009.

3. GuoY, LiP, TangJ, et al. Prevalence of atopic dermatitis in Chinese children aged 1-7 ys[J]. Sci Rep, 2016, 6(1): 29751. DOI: 10.1038/srep29751.

4. 何晓金, 钟旭丽, 肖迪, 等. 某院2005—2024年儿童抗菌药物不良反应帕累托法分析[J]. 中国现代应用药学, 2025, 42(8): 1405-1411.HeXJ, ZhongXL, XiaoD, et al. Pareto Analysis of Adverse Drug Reactions Induced by Antibacterial Drugs in Children in a Hospital from 2005 to 2024[J]. Chinese Journal of Modern Applied Pharmacy. 2025, 42(8):1405-1411. DOI: 10.13748/j.cnki.issn1007-7693.20243387.

5. 张玉. 特应性皮炎药物治疗与药学监护中国专家共识[J]. 中国医院药学杂志, 2024, 44(20): 2315-2333.ZhangY. Chinese expert consensus on drug therapy and pharmaceutical care of atopic dermatitis[J]. Chinese Journal of Hospital Pharmacy, 2024, 44(20): 2315-2333. DOI: 10.13286/j.1001-5213.2024.20.01.

6. PenaJ, ZamezaPA, PixleyJN, et al. A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis[J]. Allergy Clin Immunol Pract, 2023, 11(5): 1347-1359. DOI: 10.1016/j.jaip.2023.03.022.

7. LugerT, AugustinM, LambertJ, et al. Unmet medical needs in the treatment of atopic dermatitis in infants: An expert consensus on safety and efficacy of pimecrolimus[J]. Pediatric Allergy Immunol, 2021, 32(3): 414-424. DOI: 10.1111/pai.13422.

8. PallerAS, de Bruin-WellerM, MarcouxD, et al. Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in atopic dermatitis[J]. J Am Acad Dermatol, 2025, 92(2): 242-251. DOI: 10.1016/j.jaad.2024.09.046.

9. KawamotoN, MuraiH, NogamiK, et al. Efficacy and safety of systemic targeted therapies for atopic dermatitis in children: A systematic review and meta-analysis[J]. Allergol Int: Official Journal of the Japanese Society of Allergol, 2025, 74(3): 424-434. DOI: 10.1016/j.alit.2024.11.007.

10. 蒋元涛, 张泽华, 戴哲, 等. 数字经济领域的研究述评、热点主题与新兴趋势——基于文献计量学的分析[J]. 技术经济, 2022, 41(12): 77-90.JiangYT, ZhangZH, DaiZ, et al. Research review, hot topics and emerging trends in the field of digital economy——analysis based on Bibliometrics[J]. Journal of Technology Economics, 2022, 41(12): 77-90. DOI: 10.3969/j.issn.1002-980X.2022.12.007.

11. 闫园园, 唐红波, 阴赪宏, 等. 基于CiteSpace的国内外妊娠期用药研究文献分析[J]. 中国药房, 2020, 31(10): 1239-1246.YanYY, TangHB, YinCH, et al. Literature analysis of domestic and foreign drug use in pregnancy period based on CiteSpace[J]. China Pharmacy, 2020, 31(10): 1239-1246. DOI: 10.6039/j.issn.1001-0408.2020.10.16.

12. 李杰, 陈超美. Citespace:科学文献中的文本挖掘与可视化[M]. 第三版. 北京: 首都经济贸易大学出版社, 2022: 72-82.

13. ZhouX, KangC, HuY, et al. Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis via CiteSpace[J]. Front Public Health, 2023, 11: 1021378. DOI: 10.3389/fpubh.2023.1021378.

14. 陈悦, 陈超美, 刘则渊, 等. CiteSpace 知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253.ChenY, ChenCM, LiuZY, et al. The methodology function of Cite Space mapping knowledge domains[J]. Studies in Science of Science, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.

15. 王梅, 裴文杰, 马韶君. 我国研究生教育研究领域作者合作网络的特征分析——基于 CSSCI数据库的可视化研究(2001—2015)[J]. 研究生教育研究, 2017,(6): 29-35.WangM, PeiWJ, MaSJ. Analysis of characteristics of the author cooperation networks for postgraduate education research in China ——based on the visualization research on CSSCI database (2001-2015)[J]. Journal of Graduate Education, 2017,(6): 29-35. DOI: 10.3969/j.issn.2095-1663.2017.06.007.

16. 吴悦, 李朝旭. 中国空间隐喻研究现状与发展趋势——基于 CiteSpace 的知识图谱分析[J]. 心理学探新, 2020, 40(4): 302-308, 384.WuY, LiCX. Current status and trend of spatial metaphor research in China: based on knowledge mapping analysis of CiteSpace[J]. Psychological Exploration, 2020, 40(4): 302-308, 384. DOI: CNKI:SUN:XLXT.0.2020-04-003.

17. 凌曦, 赵志刚, 李新刚. 人工智能技术在药学领域的应用——基于Web of science的文献可视化分析[J]. 中国药房, 2019, 30(4): 433-438.LingX, ZhaoZG, LiXG. Application of artificial intelligence technology in pharmaceutical field:visualization analysis of literature based on Web of Science[J]. China Pharmacy, 2019, 30(4): 433-438. DOI: 10.6039/j.issn.1001-0408.2019.04.01.

18. 黄桂华, 杜化荣, 宫丽昆. 近五年药物警戒国际领域研究态势分析及对我国的启示[J]. 中国药物警戒, 2018, 15(5): 268-275.HuangGH, DuHR, GongLK. Analysis on global research trends of pharmacovigilance in recent five years and its implica-tions for China[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 268-275. DOI: 10.3969/j.issn.1672-8629.2018.05.004.

19. BeckLA, BieberT, WeidingerS, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diver-sity in adults with moderate-to-severe atopic dermatitis: Analy-sis of microbial diversity in ECZTRA 1, a randomized controlled trial[J]. J Am Acad Dermatol, 2023, 88(4): 816-823. DOI: 10.1016/j.jaad.2022.11.047.

20. EichenfieldL F, HoV, MatsunagaJ, et al. Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in japanese infants and children with atopic dermatitis[J]. J Dermatol, 2007, 34(4): 231-236. DOI: 10.1111/j.1346-8138. 2007.00259.x.

21. ThaçiD, SimpsonE L, BeckL A, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial[J]. Lancet, 2016, 387(10013): 40-52. DOI: 10.1016/S0140-6736(15)00388-8.

22. HanifinJM. Progress in understanding atopic dermatitis[J]. J Invest Dermatol, 2018, 138(12): e93-e95. DOI: 10.1016/j.jid.2018.10.004.

23. Eichenfield, LF, Simpson, EL, Armstrong, AW, et al. 52-week disease control and safety with as-needed application of ruxolitinib cream in children aged 2 to 11 years with mode-rate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study[J]. J Am Acad Dermatol, 2025, 93(3): AB100. DOI: 10.1016/j.jaad. 2025.05.402.

24. PallerAS, SimpsonEL, SiegfriedEC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: A randomised, double-blind, placebo-contro-lled, phase 3 trial[J]. Lancet, 2022, 400(10356): 908-919. DOI: 10.1016/S0140-6736(22)01539-2.

25. AriA, FinkJB. Recent advances in aerosol devices for the delivery of inhaled medications[J]. Expert Opin Drug Deliv, 2020, 17(2): 133-144. DOI: 10.1080/17425247. 2020.1712356.

26. 魏瑞斌, 蒋倩雯, 张瑞丽. 基于文献共被引和共词分析的研究方法的比较研究——以共词分析和内容分析为例[J]. 情报杂志, 2019, 38(2): 36-42,4.WeiRB, JiangQW, ZhangRL. Comparative study of ｒesearch method based on document Co-citation and Co-words analysis-taking the example of Co-words analysis and content analysis[J]. Journal of Intelligence, 2019, 38(2): 36-42,4. DOI: 10.3969/j.issn.1002-1965.2019.02.006.

27. SimpsonEL, PallerAS, SiegfriedEC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial[J]. JAMA Dermatol, 2020, 156(1): 44-56. DOI: 10.1001/jamadermatol. 2019.3336.

28. PallerAS, SiegfriedEC, ThaçiD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial[J]. J Am Acad Dermatol, 2020, 83(5): 1282-1293. DOI: 10.1016/j.jaad.2020.06.054.

29. WollenbergA, BarbarotS, BieberT, et al. Consensus-based european guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I[J]. J Eur Acad Dermatol Venereol, 2018, 32(5): 657-682. DOI: 10.1111/jdv.14891.

30. EichenfieldLF, LuckyAW, BoguniewiczM, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents[J]. J Am Acad Dermatol, 2002, 46(4): 495-504. DOI: 10.1067/mjd.2002.122187.

31. WahnU, BosJD, GoodfieldM, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children[J]. Pediatrics, 2002, 110(1): e2-e2. DOI: 10.1542/peds.110.1.e2.

32. AhujaK, IssaCJ, NedorostST, et al. Is food-triggered atopic dermatitis a form of systemic contact dermatitis?[J]. Clin Rev Allergy Immunol, 2024, 66(1): 1-13. DOI: 10.1007/s12016-023-08977-x.